Results 211 to 220 of about 69,801 (269)

A Holistic Wellness Prescription for Parkinson's Disease: Evidence‐Based Perspectives and Unmet Needs

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background In modern medicine the concept of wellness is often accompanied by various misconceptions arising from several factors, including a lack of clear definitions, the commercialization of wellness, and prevailing biases and stereotypes.
Indu Subramanian   +40 more
wiley   +1 more source

Enhancing Selective Brain Cancer Therapy: Integrating Nanomedicine and Molecular Dynamics to Target the Cancerous Lipid Composition

open access: yesNano Select, EarlyView.
Improving selectivity within therapeutic design is critical to ensure targeted delivery to brain tumors. Targeting the cellular membrane composition distinctive of the blood–brain barrier and brain cancer cells is explored in this review. Nanomedicine can be utilized for precise tumor recognition, and detailed mechanistic interactions of therapeutics ...
Mahnoor Kadri   +2 more
wiley   +1 more source

The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective

open access: yesObesity, EarlyView.
ABSTRACT The off‐label use of glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) among people without obesity and/or diabetes is rapidly expanding, despite a lack of clinical justification or safety data in this population. This Perspective explores the sociomedical dimensions of this trend, highlighting key research gaps and emerging hypotheses ...
Fernanda Baeza Scagliusi   +5 more
wiley   +1 more source

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

open access: yesObesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo   +4 more
wiley   +1 more source

Weekly Subcutaneous VK2735, a GIP/GLP‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

open access: yesObesity, EarlyView.
Four doses of VK2735 and a placebo group were included in the VENTURE study. Adults who were overweight or had obesity had significant weight loss when taking any dose of VK2735 for 13 weeks. More people lost at least 10% of their body weight as the dose increased.
Harold E. Bays   +9 more
wiley   +1 more source

Elevated serum aminotransferases in an infant with failure to thrive: A clinicopathological case report

open access: yes
JPGN Reports, EarlyView.
Jamie M. Klapp   +4 more
wiley   +1 more source

Addition of Phentermine‐Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double‐Blind Randomized Clinical Trial

open access: yesObesity, EarlyView.
ABSTRACT Objective This study compared the effects of phentermine‐topiramate‐ER (mid‐dose 7.5/46 mg) versus placebo on weight loss and cardiovascular disease (CVD) risk outcomes when used as an adjunct to a digitally enhanced lifestyle intervention (DELI).
Alejandro Campos   +15 more
wiley   +1 more source

Pharmacology and Regulation of Appetite and Food Intake

open access: yesPharmacology Research & Perspectives
Fernando Capela e Silva   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy